Tellgen Corporation research, development, production, and sales of in-vitro diagnostic products in China and internationally. The company offers fully automatic flow fluorescence analyzer and CLIA analyzer; molecular test such as HPV test, lung cancer, colon cancer, personalized medicine, and infertility; and automatic integrated gene detection systems. It also provides tumor detection products; HPV nucleic acid testing products; methylation mutation detection products; detection products for invasive fungal diseases. The company was founded in 2003 and is based in Shanghai, China.
Research context
Tellgen Corporation appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Tellgen Corporation is currently in a long term uptrend where the price is trading 29.0% above its 200 day moving average.
From a valuation standpoint, the stock is 31.9% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 12.7.
Tellgen Corporation's total revenue rose by 31.2% to $153M since the same quarter in the previous year.
Its net income has dropped by 2.7% to $42M since the same quarter in the previous year.
Finally, its free cash flow grew by 93.7% to $25M since the same quarter in the previous year.
Based on the above factors, Tellgen Corporation gets an overall score of 3/5.